These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 12791187

  • 1. Pharmacokinetics and tissue distribution of iv injection of polyphase liposome-encapsulated cisplatin (KM-1) in rats.
    Wang S, Mi JB, Li YZ, Chang WB, Ci YX, Zhao MZ, Zhao YK, Zhu LY, Xu G.
    Acta Pharmacol Sin; 2003 Jun; 24(6):589-92. PubMed ID: 12791187
    [Abstract] [Full Text] [Related]

  • 2. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice.
    Júnior AD, Mota LG, Nunan EA, Wainstein AJ, Wainstein AP, Leal AS, Cardoso VN, De Oliveira MC.
    Life Sci; 2007 Jan 23; 80(7):659-64. PubMed ID: 17141809
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
    Verschraagen M, Boven E, Ruijter R, van der Born K, Berkhof J, Hausheer FH, van der Vijgh WJ.
    Clin Pharmacol Ther; 2003 Aug 23; 74(2):157-69. PubMed ID: 12891226
    [Abstract] [Full Text] [Related]

  • 4. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, ten Bokkel Huinink WW, Schot M, Welbank H, Voest EE, Beijnen JH, Schellens JM.
    Cancer Chemother Pharmacol; 2002 Mar 23; 49(3):201-10. PubMed ID: 11935212
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and tissue distribution of novel traditional Chinese medicine-platinum anticancer agents in rats.
    Wang X, Au-Yeung SC, Ho YP.
    J Inorg Biochem; 2007 Jun 23; 101(6):909-17. PubMed ID: 17428541
    [Abstract] [Full Text] [Related]

  • 6. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.
    Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA.
    Cancer Chemother Pharmacol; 1999 Jun 23; 43(1):1-7. PubMed ID: 9923534
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
    Vadiei K, Siddik ZH, Khokhar AR, al-Baker S, Sampedro F, Perez-Soler R.
    Cancer Chemother Pharmacol; 1992 Jun 23; 30(5):365-9. PubMed ID: 1505075
    [Abstract] [Full Text] [Related]

  • 8. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
    Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, Joseph E, Hamburger DR, Working PK, Colbern G, Tonda ME, Potter DM, Eiseman JL.
    Cancer Chemother Pharmacol; 2004 Apr 23; 53(4):329-36. PubMed ID: 14673619
    [Abstract] [Full Text] [Related]

  • 9. Biodistribution analysis of cisplatin in liposomal form in animals with cisplatin-resistant and cisplatin-sensitive carcinoma.
    Nosko MM, Pivnyuk VM, Solyanik GI, Kulik GI, Todor IN, Momot VY, Melnikov OR, Ponomareva OV, Chekhun VF.
    Exp Oncol; 2010 Mar 23; 32(1):40-3. PubMed ID: 20355294
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
    Silva H, Silva AC, Lemos FO, Monte-Neto RL, Fontes AP, Lopes MT, Frézard F.
    Anticancer Drugs; 2013 Feb 23; 24(2):131-9. PubMed ID: 23011234
    [Abstract] [Full Text] [Related]

  • 12. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
    Hanada K, Asano K, Nishimura T, Chimata T, Matsuo Y, Tsuchiya M, Ogata H.
    J Pharm Pharmacol; 2008 Mar 23; 60(3):317-22. PubMed ID: 18284811
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Transplacental passage of Pt after treatment with the new triamine complex cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N4]-chloride platinum (II) monohydrochloride monohydrate.
    Ognio E, Chiavarina B, Caviglioli G, Lapide M, Viale M.
    Arch Toxicol; 2004 Oct 23; 78(10):584-8. PubMed ID: 15150682
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
    Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Hamburger DR, Delauter BJ, Grim A, Zuhowski EG, Joseph E, Pluim D, Potter DM, Eiseman JL.
    Clin Cancer Res; 2002 Sep 23; 8(9):2992-9. PubMed ID: 12231546
    [Abstract] [Full Text] [Related]

  • 17. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin.
    Veal GJ, Griffin MJ, Price E, Parry A, Dick GS, Little MA, Yule SM, Morland B, Estlin EJ, Hale JP, Pearson AD, Welbank H, Boddy AV.
    Br J Cancer; 2001 Apr 20; 84(8):1029-35. PubMed ID: 11308249
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.
    Staffhorst RW, van der Born K, Erkelens CA, Hamelers IH, Peters GJ, Boven E, de Kroon AI.
    Anticancer Drugs; 2008 Aug 20; 19(7):721-7. PubMed ID: 18594214
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.